Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. CEO Jay R. Luly, Ph.D., will lead the presentation, which will be available via a live webcast on Enanta's website. Following the event, a replay will be accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including COVID-19, respiratory syncytial virus, and hepatitis B, backed by royalties from its successful hepatitis C collaborations with AbbVie.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT.

A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005027/en/

Media and Investor Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When is Enanta Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Enanta Pharmaceuticals is presenting on January 10, 2023, at 3:00 p.m. PT.

Who will present for Enanta Pharmaceuticals at the conference?

Jay R. Luly, Ph.D., President and CEO, will present for Enanta Pharmaceuticals.

How can I watch the Enanta Pharmaceuticals conference presentation?

The presentation can be accessed via a live webcast on Enanta's 'Investors' page on their website.

Will there be a replay of the Enanta Pharmaceuticals presentation?

Yes, a replay will be available for approximately 30 days after the presentation.

What disease targets is Enanta Pharmaceuticals focusing on?

Enanta Pharmaceuticals is developing drugs for respiratory syncytial virus, SARS-CoV-2 (COVID-19), and hepatitis B.